



"n" n is an integer ranging from 1 to 6-8, preferably 1 to 4. The carbon chains which 'in' represents may be either linear or branched 6, wherein if n is an integer ranging from 3 to 6, the carbon chain is linear or branched,

or a derivative, analog, tautomeric form, stereoisomer, polymorph, pharmaceutically acceptable salt  
or solvate thereof.

2. (Currently amended) A The compound according to claim [[-]]1, which is selected from the group consisting of:

11-(2-N,N-Dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole hydrochloride salt;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2-,1-a]indole maleic acid salt;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-indolo[2,1-a]indole D,L-malic acid salt;

2-Chloro-11-(2-N,N-dimethylamino- ethyl)-6H-isoindolo[2,1-a]indole oxalate salt;

2-Chloro-11-(2-N,N-dimethyl- aminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;

2-Fluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole citrate salt:

2-Fluoro-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N-cyclopropyl-N-methylaminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;

2-Fluoro-11-(2-N-cyclopropyl-N-methylaminoethyl)-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylaminoethyl)-2-methyl-6H-isoindolo[2,1--a]indole;

11-(2-N,N-Dimethylaminoethyl)-2-methoxy-6H-isoindolo[2,1-a]indole;  
 2-Bromo-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 2-Bromo-11-(2-N-methyl-N-cyclopropylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 4-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 3,4-Dichloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 1-Chloro-11-(2-N,N-dimethylaminoethyl)-4-methyl-6H-isoindolo[2,1-a]indole;  
 3-Chloro-11-(2-N,N-dimethylaminoethyl)-4-methyl-6H-isoindolo[2,1-a]indole;  
 3-Chloro-11-[(2-N-methylamino)ethyl]-4-methyl-6H-isoindolo[2,1-a]indole;  
 3-Chloro-11-[(2-N-methyl-N-acetylamino)ethyl]-4-methyl-6H-isoindolo[2,1-a]indole;  
 3-Chloro-11-[(2-N-methylamino)ethyl]-2-methoxy-6H-isoindolo[2,1-a]indole;  
 3-Chloro-11-[(2-N-methylamino)ethyl]-2-sulfoamido-6H-isoindolo[2,1-a]indole;  
 3-Iodo-11-[(2-N-methylamino)ethyl]-2-methoxy-6H-isoindolo[2,1-a]indole;  
 11-(2-N,N-Dimethylaminoethyl)-4-trifluoromethyl-6H-isoindolo[2,1-a]indole;  
 2,4-Difluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 11-(2-Pyrrolidin-1-ylethyl)-6H-isoindolo[2,1-a]indole;  
 2-Bromo-11-(2-pyrrolidin-1-ylethyl)-6H-isoindolo[2,1-a]indole;  
 11-(2-(Piperidin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole;  
 11-(2-(4-Methylpiperazin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole;  
 11-(3-(Pyrrolidin-1-yl)-1-hydroxyprop-1-yl)-6H-isoindolo[2,1-a]indole;  
 2-Bromo-11-(3-(piperidin-1-yl)-1-hydroxyprop-1-yl)-6H-isoindolo[2,1-a]indole;  
 11-(2-N,N-Dimethylaminoethyl)-4-ethyl-6H-isoindolo[2,1-a]indole;  
 11-(2-N,N-Dimethylamino-1-hydroxyethyl)-6H-isoindolo[2,1-a]indole;  
 11-(2-N,N-Dimethylaminoethyl)-4-methoxy-6H-isoindolo[2,1-a]indole;  
 2-Bromo-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 4-Bromo-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 4-Fluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;  
 2-Bromo-11-(2-(4-methylpiperazin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole; and its stereoisomers, its N-oxides, its polymorphs, its pharmaceutically acceptable salts and solvates or a stereoisomer, N-oxide, polymorph, pharmaceutically acceptable salt or solvate thereof.

4. (Currently amended) A The pharmaceutical composition according to claim[[ -]]3, which is in the form of a tablet, a capsule, a powder, ~~lozenges, suppositories,~~ a lozenge, a suppository, a syrup, a solution, a suspension or injectable an injection, wherein said form is administered in, as a single dose or in multiple dose units.

6. A method of modulating Use of compound of general formula (I), as defined in claim 1 or a pharmaceutical composition as defined in claim 3 for the treatment where a modulation of 5-HT and melatonin activity is desired in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

7. (Currently amended) A method of selectively modulating the 5-HT receptors of a patient, comprising administering to said patient Use of a therapeutically effective amount of a compound as claimed in according to claim[[-]]1 for the manufacture of a medicament for the treatment and/or prevention of clinical conditions for which a selective action on 5-HT receptors is indicated.

12. (Currently amended) ~~Use of a radiolabelled compound as claimed in claim 1, as a diagnostic tool for~~ A method of modulating 5-HT receptor function in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1, wherein the

14. (Cancelled)

16. (Currently amended) A method for the treatment and/or prophylaxis of mild cognitive impairment, ~~and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and or~~ Huntington's chorea in a patient, which comprises administering to [[a]] said patient in need thereof~~[[, an]]~~ a therapeutically effective amount of a compound of general formula (I) as claimed in ~~Claim 1~~ according to claim 1.

17. (Currently amended) A method for the treatment of certain GI (Gastrointestinal) disorders such as IBS (Irritable irritable bowel syndrome) or chemotherapy induced emesis using a compound of general formula (I) as claimed in Claim 1 in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

18. (Currently amended) A method ~~to reduce~~ of reducing in a patient morbidity and mortality associated with ~~the excess weight using a compound of general formula (I) as claimed in Claim 1,~~ comprising administering to the patient a therapeutically effective amount of a compound according to claim 1.

19. (Cancelled)